Olatec Therapeutics’ Post

Tomorrow is #NationalNonprofitDay — a day to celebrate the impact of organizations dedicated to serving the public good. NP2 is a nonprofit pharmaceutical corporation that puts patients ahead of profits and works to reduce the cost of life-saving drugs. We believe that no one in America should go broke or forego medical care because of high drug prices. NP2 was incorporated as a nonprofit to ensure that we would never be bought and that our mission and goals would remain steadfast and uncompromised. We’re here for the long haul, committed to lowering the price of life-saving drugs and making a difference in the lives of those we serve. Please consider donating today to help us bring about needed change in the pharmaceutical industry in America. #Nonprofit #Pharma #DonateToday https://lnkd.in/gRmiDRw4

In the August Issue of AmStat News, I highlight a new program at the American Statistical Association - the ASA Legacy Page. It's the perfect way to honor the accomplishments of the statistician or data scientist in your life. It also raises funds for important ASA programs to support the future of our profession. And it brings me great joy that Dionne Price is the first recipient of a Legacy Page made possible by generous donations given in her memory. Want to honor a colleague or loved one? Reach out to Amanda Malloy to get started. American Statistical Association - ASA, ASA Biopharmaceutical Section #statistics #datascience

Plasma donation is so important

It is a privilege to serve as an advisor to the Lupus Research Alliance (LRA). We reviewed highly innovative and promising research proposals submitted to LRA's Translational Bridge Award program on Monday, June 10, 2024. These proposals aim to combat lupus and associated diseases, bringing promising drugs and technologies to fruition to help those in need. I look forward to collaborating with the Lupus Research Alliance and the Team again in August 2024. https://lnkd.in/gyzX8bS4 With 25+ years of expertise in drug development, due diligence, commercialization, and fundraising, I provide strategic consulting to advance innovative therapies and drive successful outcomes in the pharmaceutical and biotech sectors. #lupus #biotechnology #fundraising #pharmaceuticals #pharma #healthcare #medicine #innovation #strategy #leadership #business #success #duediligence #innoventyx

New on the MAPGuide: Wellcome Trust – Alto Neuroscience, Bipolar Depression Therapeutic Convertible Loan Agreement This Convertible Loan Agreement is between the Wellcome Trust, a global charitable foundation, and Alto Neuroscience, a clinical-stage biopharmaceutical company focused on neuropsychiatric care. Under the Agreement, Wellcome makes a programme-related investment by way of an unsecured convertible loan to Alto Neuroscience of up to approximately USD $11.7m. The loan may only be used to to progress the delivery of a specific Project including a Phase 2b study of Alto Neuroscience’s lead candidate (ALTO-100) in patients with bipolar depression. Alto Neuroscience must fulfill obligations including development and exploitation of the Product in the field of diagnosis, prevention and treatment of bipolar disorder, depressive phase using Reasonable Efforts to take into account Wellcome’s approach to equitable access to healthcare interventions. Within six months of making an application for marketing approval Alto Neuroscience must provide Wellcome with a marketing plan for making the Product available to end users, which may include an appropriate and proportionate global access plan setting out strategies to ensure low economic barriers to access. Alto Neuroscience must also provide reports to Wellcome for seven years after the first commercial sale of the Product in the Field detailing efforts taken to provide equitable access to the Product as well as the volume of products sold, supplied or made available for distribution. Read the full agreement here: https://lnkd.in/e4mskmiv Explore the MAPGuide here: https://lnkd.in/d6ZcxXN

Thoughts on this? >> Emmet Stephenson gives $150M to City of Hope for pancreatic cancer, creating million-dollar research prize >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #productmarketing

Thoughts on this? >> Emmet Stephenson gives $150M to City of Hope for pancreatic cancer, creating million-dollar research prize >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #pharmaceutical #healthcare

Pro Bono in the Spotlight: The Anticancer Fund 🌟 Highlighting our assistance to the Anticancer Fund, a global research and non-profit organization dedicated to finding new treatments for cancer. 𝗢𝘂𝗿 𝗿𝗼𝗹𝗲: Crowell’s Kristof Roox and Wietse Vanpoucke advise the Anticancer Fund on the EU pharmaceutical package, a regulation aimed at making the pharmaceutical system patient-centered and ensuring that patients benefit from equitable access to safe and affordable therapies. 𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: The Anticancer Fund repurposes non-cancer drugs for oncology, to address the urgent need for effective and accessible cancer treatments. 💬 “Working with the Anticancer Fund has been an incredibly rewarding experience. It’s inspiring to contribute to a cause that is making such a significant difference in the fight against cancer.” — Wietse Vanpoucke At Crowell, we believe in using our legal expertise and human resources to make a positive impact. Public service and supporting pro bono initiatives align with our commitment to giving back to our community. For more information about the Anticancer Fund ➡️ https://lnkd.in/gPTKMGe #ProBono #AnticancerFund #MakingADifference

The Impact of Marijuana Use on Organ Transplants: Myth Busted! Discover the truth about the infectious risks associated with organ donation from marijuana users. Our study reveals that recent marijuana use does not increase the likelihood of infections, graft failure, or death for recipients. Let's debunk the inconsistent guidance on cannabis use and organ donation. #OrganTransplant #MarijuanaMyths #TransplantInfections #OrganDonation #MedicalResearch #CannabisDebunked #HealthcareInsights #OrganHealth #TransplantSuccess #MedicalMyths

The EFPIA yearly W.A.I.T indicator survey describing patients' access to approved medicines in the EU for 2023 is now published. It shows large variation across the EU countries. Below is the breakdown for oncology drugs with full (green) and limited (yellow) availability. Link to the report: https://lnkd.in/d9jxN8R8 #marketaccess #EU